Page 846 - Cardiac Nursing

9 P
Apt
d
p79
5
/
0
M
9
9
Pa
qx
2
qx
g
9-8
2
Pa
a
009
ar
6
LWB
LWBK340-c35_p799-822.qxd 29/06/2009 08:59 PM Page 822 Aptara
22
LWB K34 0-c 3 5 _ _ p79 9-8 22. qx d 2 9 / 0 6 / / 2 009 0 8: 5 9 P M Pa g e 8 22 Apt ar a
K34
0-c
K34
3
3
009
5
22.
9-8
22.
0
e 8
8:
8:
822 PA R T V / Health Promotion and Disease Prevention
195. MRC Working Party. (1992). Medical Research Council trial of treatment 217. Neusy, A. J., & Lowenstein, J. (1989). Blood pressure and blood pressure
4
4
of hypertension in elderly: Principal results. BMJ, 304(6824), 405–412. variability following withdrawal of propranolol and clonidine. Journal of
9
196. SHEP Cooperative Research Group. (1991). Prevention of stroke by an- Clinical Pharmacology, 29(1), 18–24.
9
tihypertensive drug treatment in older persons with isolated systolic hy- 218. Vidt, D. G. (1999). Management of hypertensive emergencies and ur-
pertension: Final results of the Systolic Hypertension in the Elderly Pro- gencies. In J. L. Izzo Jr. & H. R. Black (Eds.), Hypertension primer (2nd
5
gram (SHEP). JAMA, 265, 3255–3264. ed., pp. 437–440). Baltimore: Lippincott Williams & Wilkins.
5
197. Staessen, J. A., Fagard, R., Thijs, L., et al. (1997). Randomised double- 219. Grossman, E., Messerli, F. H., Grodzicki, T., et al. (1996). Should
blind comparison of placebo and active treatment for older patients with a moratorium be placed on sublingual nifedipine capsules given for
6
0
0
6
isolated systolic hypertension. Lancet, 350, 757–764. hypertensive emergencies and pseudoemergencies? JAMA, 276(16),
198. MacMahon, S., & Rodgers, A. (1993). The effects of blood pressure reduc- 1328–1331.
tion in older patients: An overview of five randomized controlled trials in 220. Varon, J., & Marik, P. E. (2000). The diagnosis and management of hy-
5
elderly hypertensives. Clinical Experience in Hypertension, 15(6), 967–978. pertensive crises. Chest, 118(1), 214–227.
5
199. Hansson, L., Lindholm, L. H., Ekbom, T., et al. (1999). Randomised 221. Miller, N. H., Hill, M., Kottke, T., et al. (1997). The multilevel compli-
trial of old and new antihypertensive drugs in elderly patients: Cardio- ance challenge: Recommendations for a call to action. A statement for
vascular mortality and morbidity the Swedish Trial in Old Patients with healthcare professionals. Circulation, 95(4), 1085–1090.
4
4
Hypertension-2 study. Lancet, 354(9192), 1751–1756. 222. Ebrahim, S. (1998). Detection, adherence and control of hypertension
200. Black, H. R. (1999). Management of hypertension in older persons. In for the prevention of stroke: A systematic review. Health Technology As-
J. L. Izzo Jr. & H. R. Black (Eds.), Hypertension primer (2nd ed., sessment, 2(11), 1–78.
pp. 430–432). Baltimore: Lippincott, Williams & Wilkins. 223. Roter, D. L., Hall, J. A., Merisca, R., et al. (1998). Effectiveness of in-
201. Lakka, T. A., Venalainen, J. M., Rauramaa, R., et al. (1994). Relation of terventions to improve patient compliance: A meta-analysis. Medical
6
6
leisure-time physical activity and cardiorespiratory fitness to the risk of Care, 36(8), 1138–1161.
acute myocardial infarction in men. New England Journal of Medicine, 224. Calhoun, D. A., Jones, D., Textor, S., et al. (2008). Resistant hyper-
0
0
330, 1549–1554. tension: Diagnosis, evaluation, and treatment. A scientific statement
V
202. Vita, A. J., Terry, R. B., Hubert, H. B., et al. (1998). Aging, health risks, and from the American Heart Association Professional Education Commit-
V
8
8
cumulative disability. New England Journal of Medicine, 338, 1035–1041. tee of the Council for High Blood Pressure Research. Hypertension, 51,
203. Flack, J. M., Nassar, S. A., Britton, M., et al. (2007). Hypertension in 1403–1419.
racial and ethnic minorities. In G. Lip & J. E. Hall (Eds.), Comprehen- 225. Working Group to Define Critical Patient Behaviors in High Blood Pres-
sive hypertension. Philadelphia: Mosby, Elsevier. sure Control. (1979). Critical patient behaviors in high blood pressure
204. Douglas, J. G., Bakris, G. L., Epstein, M., et al. (2003). Management of control: Guidelines for professionals. JAMA, 241, 2534–2537.
high blood pressure in African Americans: Consensus statement of the Hy- 226. Bakris, G., Bohm, M., Dagenais, G., et al. (2008). Cardiovascular pro-
pertension in African Americans Working Group of the International Soci- tection for all individuals at high risk: Evidence-based best practice. Clin-
7
7
ety on Hypertension in Blacks. Archives of Internal Medicine, 163, 525–541. ical Research in Cardiology, 97(10), 713–725.
205. Borzecki, A. M., Oliveria, S. A., & Berlowitz, D. R. (2005). Barriers to 227. Coordinating Committee of the National High Blood Pressure Educa-
9
hypertension control. American Heart Journal, 149(5), 785–794. tion Program. (1984). Collaboration in high blood pressure control:
9
206. Report of the National High Blood Pressure Education Program Work- Among professionals and with the patient. Annals of Internal Medicine,
ing Group on High Blood Pressure in Pregnancy. (2000). American Jour- 101(3), 393–395.
nal of Obstetrics and Gynecology, 183(1), S1–S22. 228. Curzio, J. L., Rubin, P. C., Kennedy, S. S., et al. (1990). A comparison
207. Sibai, B. M. (1996). Treatment of hypertension in pregnant women. of the management of hypertensive patients by nurse practitioners com-
New England Journal of Medicine, 335(4), 257–265. pared with conventional hospital care. Journal of Human Hypertension,
208. Lindholm, L. H., Ibsen, H., Dahlof, B., et al. (2002). Cardiovascular 4 4 4(6), 665–670.
morbidity and mortality in patients with diabetes in the Losartan Inter- 229. Logan, A. G., Milne, B. J., Achber, C., et al. (1979). Work-site treatment
vention For Endpoint reduction in hypertension study (LIFE): A ran- of hypertension by specially trained nurses. A controlled trial. Lancet,
domised trial against atenolol. Lancet, 359(9311), 1004–1010. 2(8153), 1175–1178.
9
9
209. Mehler, P. S., Coll, J. R., Estacio, R., et al. (2003). Intensive blood pres- 230. Pheley, A. M., Terry, P., Pietz, L., et al. (1995). Evaluation of a nurse-
sure control reduces the risk of cardiovascular events in patients with pe- based hypertension management program: Screening, management, and
ripheral arterial disease and type 2 diabetes. Circulation, 107(5), 753–756. outcomes. Journal of Cardiovascular Nursing, 9(2), 54–61.
7
7
9
9
210. Ikeda, T., Gomi, T., Hirawa, N., et al. (1996). Improvement of insulin 231. Schultz, J. F., & Sheps, S. G. (1994). Management of patients with hy-
sensitivity contributes to blood pressure reduction after weight loss in hy- pertension: A hypertension clinic model. Mayo Clinic Proceedings,
7
pertensive subjects with obesity. Hypertension, 27(5), 1180–1186. 69(10), 997–999.
7
211. Lazarus, J. M., Bourgoignie, J. J., Buckalew, V. M., et al. (1997). 232. Smith, E. D., Merritt, S. L., & Patel, M. K. (1997). Church-based edu-
Achievement and safety of a low blood pressure goal in chronic renal dis- cation: An outreach program for African Americans with hypertension.
ease. The Modification of Diet in Renal Disease Study Group. Hyperten- Ethnic Health, 2(3), 243–253.
sion, 29(2), 641–650. 233. Rose, A. J., Berlowitz, D. R., Orner, M. B., et al. (2007). Understanding
212. Perseghin, G., Price, T. B., Petersen, K. F., et al. (1996). Increased glu- uncontrolled hypertension: Is it the patient or the provider? The Journal
cose transport-phosphorylation and muscle glycogen synthesis after exer- of Clinical Hypertension, 9(12), 937–943.
cise training in insulin-resistant subjects. New England Journal of Medi- 234. Rose, A. J., Shimada, S. L., Rothendler, J. A., et al. (2008). The accuracy
5
cine, 335, 1357–1362. of clinician perceptions of “usual” blood pressure control. Journal of Gen-
5
213. Klag, M. J., Whelton, P. K., Randall, B. L., et al. (1996). Blood pressure eral Internal Medicine, 23(2), 180–183.
and end-stage renal disease in men. New England Journal of Medicine, 235. Alderman, M. H., Furberg, C. D., Kostis, J. B., et al. (2002). Hyperten-
334, 13–18. sion guidelines: Criteria that might make them more clinically useful.
4
4
214. Klag, M. J., Whelton, P. K., Randall, B. L., et al. (1997). End-stage re- American Journal of Hypertension, 15(10, Pt. 1), 917–923.
nal disease in African-American and white men. 16-year MRFIT find- 236. Hyman, D. J., & Pavlik, V. N. (2001). Characteristics of patients with
7
7
ings. JAMA, 277(16), 1293–1298. uncontrolled hypertension in the United States. New England Journal of
215. Giatras, I., Lau, J., & Levey, A. S. (1997). Effect of angiotensin-convert- Medicine, 345(7), 479–486.
ing enzyme inhibitors on the progression of nondiabetic renal disease: A 237. Tu, K., Mamdani, M. M., & Tu, J. V. (2002). Hypertension guidelines in
meta-analysis of randomized trials. Angiotensin-Converting-Enzyme In- elderly patients: Is anybody listening? American Journal of Medicine,
hibition and Progressive Renal Disease Study Group. Annals of Internal 113(1), 52–58.
Medicine, 127(5), 337–345. 238. Farquhar, J. W., Fortmann, S. P., Flora, J. A., et al. (1990). Effects of
7
7
216. Maschio, G., Alberti, D., Janin, G., et al. (1996). Effect of the an- communitywide education on cardiovascular disease risk factors. The
5
giotensin-converting-enzyme inhibitor benazepril on the progression of Stanford Five-City Project. JAMA, 265, 359–365.
5
chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibi- 239. Puska, P., Tuomilehto, J., Nissinen, A., et al. (1989). The North Karelia
tion in Progressive Renal Insufficiency Study Group. New England Jour- project: 15 years of community-based prevention of coronary heart dis-
4
4
nal of Medicine, 334(15), 939–945. ease. Annals of Medicine, 21(3), 169–173.